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ABSTRACT

Angiogenesis and Myogenesis in a Chronic Ischemic Heart
by
Esha Ibrahim

Miniswine underwent procedures to evaluate treating chronic ischemia with the implantation of
autologous satellite cells and laser transmyocardial revascularization (TMR). The objective was
to combine two therapies to restore cardiac function. This experiment involved three surgical
procedures: (1) placing a constrictor on the coronary artery; (2) producing channels and
implanting cells; (3) obtaining samples. The swine were divided into groups: Group 1, Ischemia;
Group 2, Ischemia + Laser TMR; Group 3, Ischemia + Laser TMR+ Cells; Group 4, Ischemia +
Cells. Sonomicrometry and Millar pressure transducers were used to determine contractility, left
ventricular pressure, and pressure-volume loops. There were no significant differences (p<0.05)
among the hemodynamic data except for Group 4, which produced significantly lower output
values. Morphological evaluation revealed a significantly reduced scar area in Group 3. Although
there was a significant difference in scar area, the phenomena behind this improvement as
compared to the unimproved hemodynamic function is not understood.
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CHAPTER 1
INTRODUCTION

Despite a significant advance in its prevention and treatment, coronary artery disease
(CAD) remains the leading cause of death. According to the American Heart Association, nearly
13 million people in the United States suffer from some form of CAD. CAD is the most
significant chronic condition and the leading cause of death for all segments of society.
Conventional treatment for the disease includes medical therapies to reduce the risk factors, to
reduce myocardial oxygen consumption, and to prevent progression of the disease; and
interventional therapies are intended to restore the coronary artery blood flow either by
angioplasty or surgery bypass (Braunwald 1997). These approaches, however, are limited by the
development over time of native vessel narrowing and graft occlusions. There are a growing
number of patients suffering from angina who, despite continued technical advances, cannot be
treated by these conventional therapies. Accordingly, there is interest in exploring alternative
forms of therapy to ameliorate angina symptoms and improve blood flow to ischemic
myocardium. Transmyocardial revascularization is a newly-developed surgical treatment for
patients with symptomatic end-stage coronary artery disease who are not candidates for
conventional revascularization. Although it is still unresolved as to how laser transmyocardial
revascualrization achieves therapeutic effects, a growing amount of clinical and experimental
evidence suggests that laser transmyocardial revascularization-induced angiogenesis plays an
important role in this therapeutic approach.
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Transmyocardial Revascularization (TMR)
Transmyocardial Revascularization (TMR) is a fairly new alternative treatment for
patients with advanced coronary disease whose anatomy is not amenable to percutaneous
coronary intervention or conventional coronary artery bypass graft surgery (CABG) (Allen et al.
2004). During TMR, small “channels,” or holes, are created in the heart via a laser device applied
to the myocardial surface (See Figure 1).

Figure 1. Laser Hand-piece in Contact with Myocardium (PLC Medical Systems, Milford, MA)
The concept was based on the ability to achieve adequate myocardial perfusion by the creation of
direct transmural channels through the ventricle. It is thought, as Figure 2 portrays, that the
injury produced by the laser energy may result in the elaboration of vascular growth factors that
stimulate angiogenesis (Horvath 2004a).
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Figure 2. Illustration showing a Proposed Mechanism for TMR Effectiveness
(PLC Medical Systems, Milford, MA) The injury to the myocardium elicited by the laser is
thought to generate angiogenesis indirectly.
The application of TMR into clinical practice has been rapid and potentially driven by
multiple factors. First, TMR represents one of the few existing treatment options for patients
experiencing angina who do not qualify as candidates for traditional revascularization (Horvath
2004). In these patients, clinical trials have shown that TMR provided favorable symptomatic
effect in many patients. Lastly, TMR requires little additional educational or technical training to
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administer and commands professional fees similar to those required for traditional bypass surgery
(Abo-Auda and Benza 2003).
It has been demonstrated that transmyocardial laser channels failed to acutely increase
regional myocardial blood flow (Lutter and Yoshitake 1998). However, laser TMR is still being
used to treat patients with diffuse coronary artery disease who are not amenable to conventional
procedures (Samuels et al. 2004). The clinical experience with laser TMR indicates that angina is
significantly relieved, perfusion and treadmill tolerance improved, and hospital admissions are
decreased. The mechanism which facilitates reported laser TMR-related improvements remains
something of a mystery.

Angiogenesis Hypothesis.
Several experimental studies have shown increases in vascularization which supports the
angiogenesis hypothesis as an explanation for the unexplained phenomena behind Transmyocardial
Revascularization. These studies have used a variety of methods to create the transmural
channels: needles, variety of lasers, radio frequency energy, and growth factors. Nearly all
devices investigated for TMR have succeeded in inducing angiogenesis in some form. Therefore,
many investigators believe that angiogenesis could just be part of the normal healing process
following myocardial injury.
Perfusion analysis has also provided evidence to support TMR. Because myocardial
ischemia is primarily endocardial and typically not completely transmural, physiological
redistribution of perfusion is more likely after TMR (Whittaker and Kloner 1997). Experimental
results from procedures using swine evaluated at longer time intervals showed a significant
11

improvement in perfusion lending further support to the angiogenesis hypothesis. Human trials
evaluating laser TMR have not shown perfusion improvements like those seen in animal studies,
and currently there is no a sufficient explanation for this unfortunate difference.

Cellular Cardiomyoplasty
Cellular cardiomyoplasty is a procedure using cell transplantation to repair a damaged
myocardium. Previous studies have shown evidence that syngeneic myoblast implantation
following a myocardial infarction will elicit improved ventricular function (Jain et al. 2001). After
years of investigation into the potential of using skeletal muscle cell grafting for cardiac repair,
Menasche and his colleagues conducted the first clinical trial using skeletal myoblasts for MI
repair eliciting encouraging results (Menasche et al. 2003).

Satellite Cells: Identification and Significance
Kao and colleagues have been using autologous satellite cell implants from the skeletal
muscle of dogs even prior to 1989 (Kao et al. 1989). The satellite cells have been effectively
harvested, labeled, and implanted into the injured heart to elicit new muscle formation and
functional restoration (Jackson et al 2001). Other investigators have shown experimental results
which support the implantation of autologous satellite cells from skeletal muscle as a potential
approach for myocardial repair and functional improvement (Lash et al. 1957).
It is has been verified that unlike cardiac muscle, skeletal muscle maintains regenerative
capabilities (Garrett and Best 1994). In 1961, Mauro first described the satellite cells of the
skeletal muscle of a frog using electron microscopy. It is established that satellite cells play an
12

intricate part in skeletal muscle regeneration. The observance of the regenerative capabilities of
satellite cells in skeletal muscle led researchers to consider the regenerative potential of
myocardium (Marelli et al. 1992). This consideration led to the realization that cardiac myocytes
are terminally differentiated cells that lose their ability to undergo cell division at an early age (Li
et al. 1996).
Cellular cardiomyoplasty may prove to be more effective than coronary artery bypass graft
and percutaneous coronary intervention therapies, which work to restore perfusion as well as to
salvage dying muscle cells. Cellular cardiomyoplasty works to replace the cells that are already
dead or lost (Rumyantsev 1977). Even though recent clinical trials have shown encouraging signs
for this innovative technique, more research is critical in the area of cellular cardiomyoplasty to
further evaluate efficacy and to attempt to understand the mechanism(s) underlying this
improvement.

Satellite Cells: Muscle Repair
Over the years, it has become evident through the research of several investigators that
satellite cell proliferation and induction are trauma-related (Schultz et al. 1978). This same work
has also shown that satellite cells elicit new myofiber formation through a process analogous to
muscle histogenesis in the embryo. Following injury, muscle goes through an unambiguous
progression of healing phases. These healing phases include degeneration, inflammation,
regeneration, and scar formation (Huard and Fu 2002). Degeneration and inflammation have been
noted during the first few days after injury. Generally, regeneration begins approximately a week
after injury and lasts up to a month at most, with peak performances noted at the two-week mark.
13

Fibrosis tends to begin between the 2nd and 3rd weeks following injury and continues to grow in
size as time passes. After only a few cell divisions, satellite cell progeny start to fuse forming
multinucleated myotubes , but the continued growth of the myoblasts, though largely dependent
on the degree of injury, can persist for up to approximately 10 days (Snow 1978).
Satellite cells are located between the external lamina and sarcolemma of skeletal muscle
fibers, which can be seen in Figure 3 (Hawke and Garry 2004). The presence of organelles such
as ribosomes, rough endoplasmic reticulum, and golgi complexes implies the presence of
metabolic activity in the satellite cells of immature muscle. This is in contrast to the low volume of
such organelles found in adult muscle, which is indicative of a quiescent status. Investigators have
previously shown that with the proper environmental signals, satellite cells enter into the cell cycle
to provide the precursors necessary for new muscle formation in growth and repair (Jingbo and
Liu 2004). It is thought that the disruption of the basal lamina and plasma membrane after injury
releases the activated satellite cells.

Figure 3 Satellite Cell Location (adapted from Hawke and Garry 2001)
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The regeneration of skeletal muscle has been conveniently separated into four divisions:
(1) satellite-cell activation; (2) myoblast or precursor proliferation; (3) differentiation; (4) return
to quiescence. Satellite-cell activation is the manner by which satellite cells exit G0 and enter the
cell cycle (Hurme and Kallmo 1992). The second stage in skeletal muscle regeneration is the
proliferation of satellite cells and myogenic precursor cells. Differentiation is the process whereby
proliferating myoblasts derived from activated satellite cells and other myogenic precursors will
withdraw from the cell cycle and either fuse to existing fibers in repair of damaged segments or to
each other to form new fibers. Fusion events have been found to occur after cells exit mitosis and
enter G1 (Hurme and Kallmo 1992). The ability of satellite cells to return to quiescence has been
less thoroughly investigated than activation, proliferation, and regeneration. Under normal
conditions the proportion of satellite cells that actually reside in G0 rather than in a long lag phase
in G1 is not known, as are many important aspects of satellite-cell quiescence. For example, it is
uncertain whether the same satellite cells that originally respond to an activating stimulus will
return to quiescence, or whether the satellite cell compartment is only repopulated by daughter
cells (Shutlz and McCormick 1994).
Although the ability to identify satellite cells using histological methods will remain
controversial until their characteristics and activities are further elucidated, it is recognized that
the existence of multiple populations of myogenic precursor cells would allow muscle tissue to
respond differentially to a particular stimulus, type of injury, or physiological demand, and thereby
enable a highly controlled response (Rumyantsev 1991). The range of characteristics displayed by
muscle precursor cells is most frequently made available through experimentation using the
differences among cells isolated from muscle. For example, different lineages of muscle precursors
15

can be isolated from the variety of slow- and fast-twitch muscles in typical proportions, and each
can differentiate to express distinct profiles of protein isoforms distinctive of slow and fast muscle.
This justifies why the rectus abdominus skeletal muscle biopsy was used to isolate the satellite
cells for this particular study involving myocardial regeneration. To sustain the heart’s workload,
red muscle fibers which maintain slow fatigue characteristics are a practical selection for the repair
of the cardiac muscle (Hawke and Garry 2001).
The basis for this procedure is to use the body’s natural repair process for skeletal muscle
and extend this to the heart, because adult mammalian ventricular myocytes lack regenerative
capability. Without intervention, scar formation is the final result of myocardial injury or damage.
As long as scar is formed, complete regeneration of muscle tissue cannot occur, thus indicating
that advances towards preventing muscle fibrosis as well as techniques to promote muscle
regeneration must continue to be investigated.
The transplantation of satellite cells into an injured myocardium has resulted in improved
myocardial function, but the mechanism of this improvement remains elusive (Kiortsis et al.
1989). Also, it still seems to be a topic of controversy concerning whether transplanted satellite
cells differentiate into modified skeletal muscle fibers or into actual cardiac muscle cells, as once
hypothesized, or if what has looked like transdifferentiation is actually cell fusion or
contamination of the biopsy sample with unfamiliar progenitor cells and/or pluripotent cells that
are stimulated to form new progenitor cells of a different tissue lineage (Young and Black 2004).
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Rationale for Thesis
A significant amount of data has suggested that providing ischemic myocardium with
angiogenesis through laser TMR leads to neovascularization and to myocardial protection in the
remodeling process after chronic myocardial ischemia. Clinical observation and data have also
demonstrated that a patient’s angina symptoms can be relieved within days after laser TMR
treatment. The neovascualrization developed through anigogenesis, however, does not occur
immediately or even a few days after various laser, mechanical, or even pharmacological
stimulation. It takes at least weeks to develop new vessels in the ischemic myocardium after the
expression angiogenic factors. Does laser TMR provide an increase in regional perfusion
following chronic ischemia? Is there a significant improvement observed in cardiac function and
scar formation following elicitation of cellular cardiomyoplasty and laser TMR therapies? Is there
a greater improvement seen in global and regional contractility using two unconventional
therapies in combination as compared to each therapy treating chronic myocardial ischemia
individually? Based on these inquiries and relevant clinical research, evaluating the effectiveness of
combining two unconventional therapies is the primary objective of this thesis.
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CHAPTER 2
MATERIALS AND METHODS

Materials
Animals
Thirty miniswine, male and female, weighing 25-30kg were obtained from Harlan-Sinclair,
Indianapolis, IN.
Satellite Cells
Satellite cells were harvested from the rectus abdominus muscle at the lower chest portion
of the miniswine after the completion of the first sternatomy procedure. After isolating the cells
and allowing them to plate on the flasks, the cells were then transfected and labeled using
humanized green fluorescent protein from Renilla reniformis. (Stratagene Cloning Systems, La
Jolla, CA).
CO2 Heart Laser
Transmyocardial Laser Revascularization (TLMR) was performed using an 800-W CO2
laser (The Heart Laser, PLC Medical Systems, Milford, MA).
Ameroid Constrictor
An ameroid constrictor was used to simulate the gradual constriction of the artery over
time as coronary artery disease, inducing chronic ischemic damage (2.0mm ameroid constrictor,
Research Instruments, SW, Escondido, CA).
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Gortex Surgical Membrane
A semipermeable membrane made from expanded PolyTetraFluoroEthylene (PTFE)
(Gore, Flagstaff, AZ).
Media
* M-199 containing 1% antimycotic antibiotic solution (contains penicillin, streptomycin,
and amphotericin B) purchased from Sigma Chemical Co., (St. Louis, MO) and 10% fetal bovine
serum (Sigma Chemical Co., St. Louis, MO).
* Hank’s balanced salt solution lacking calcium and magnesium (Sigma)
Enzymes
Hyaluronidase (Sigma Chemical Co., St. Louis, MO)
Collagenase (Sigma Chemical Co., St. Louis, MO)
Trypsin containing EDTA (ATCC, Manassas, VA)
Microspheres
Non-radioactive injectable, colored ultraspheres formulated as 10 million spheres/ml
suspended in saline with Tween 80 & Thimerosal(E-Z Trac, Irvine CA).
Syringe Pump
An infusion/ withdrawal pump, model # 906 (Harvard Bioscience Co., Holliston, MA),
was used to obtain a reference blood sample for regional perfusion calculations with the
microspheres.
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Computer Program Hardware and Software
2mm crystals (Sonometrics Co., London, ON, Canada)
1mm crystals (Sonometrics Co., London, ON, Canada)
LVP Millar model # MPC-500 (Millar Instruments Inc., Houston, TX)
Arterial Millar model # SPC-350S (Millar Instruments Inc., Houston, TX)
Cardiosoft Analysis Program version 3.2.4 (Sonometrics Co., London, ON, Canada)
Methods
Study Design
A chronic ischemia myocardium swine model with an ameroid constrictor on the left
anterior descending coronary artery was designed for laser TMR and cellular cardiomyoplasty to
induce angiogenesis and myogenesis in order to improve regional blood flow along with overall
cardiac function in ischemic myocardium. The reasons for choosing this particular model wereas
follows:
1. The larger animal model makes it technically more feasible to evaluate the functional study and
to measure the regional blood flow.
2. Similar to humans, swine myocardium has little native collateral circulation

20

Experiment Time Line for In Vivo Study

Ischemia
Group

Ischemia + Laser
Group

Ischemia + Laser
+ Cells Group

Ischemia + Cells
Group

9 weeks
I--------------------------------------------------------------------I
Baseline
- Placement of LAD
occluder-

Termination &
heart extraction

3 weeks
6 weeks
I-------------------I-----------------------------------------------I
Baseline
-Placement of LAD
occluder-

TMLR treatment
& plain media injection

Termination &
heart extraction

3 weeks
6 weeks
I------------------I------------------------------------------------I
Baseline
- Placement of LAD
occluder-

TMLR treatment
& cells injection

Termination &
heart extraction

3 weeks
6 weeks
I------------------I------------------------------------------------I
Baseline
- Placement of LAD
occluder-

Cells injection
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Termination &
heart extraction

Animals
Miniswine weighing 25 to 30 kg were purchased for the proposed study. The animals
were housed in air-conditioned rooms with controlled light and dark cycles and given free access
to food and water at all times except when prepared for or under surgical procedures. After
fasting overnight and receiving preoperative treatment, each pig was anesthetized with 8mg/kg
telazol and 1mg/kg of xylazine following ear vein cannulation. The animals were intubated with a
cuffed endotracheal tube following an injection of atropine (0.05mg/kg). The surgical sites were
shaved followed by a thorough cleaning with betadine. A baseline electrocardiogram (EKG) was
obtained using a 12-lead Hewlett Packard machine. Also, the EKG was monitored throughout
the procedure with leg leads. Millar micro-tip pressure transducers were used to measure blood
pressures. Anesthesia was maintained with 1% to 2% halothane. Humane care and proper
analgesic, anesthetic, and tranquilizing drugs were provided to all experimental animals as needed.
The “ Principles of Laboratory Animal Care “ and the “ Guide for the care and use of Laboratory
Animals” were followed. The proposed study was approved by the Animal Care and Use
Committee of East Tennessee State University. Thirty experimental animals were used for
myocardial regeneration using cellular cardiomyoplasty and Laser Transmyocardial
Revascularization. The animals were categorized into four groups: Group 1, Ischemia; Group 2,
Ischemia + Laser TMR; Group 3, Ischemia + Laser TMR + Cells; Group 4, Ischemia + Cells.
The same anesthetic regimen was used for each of the three different surgical procedures.
Continuous electrocardiographic and blood pressure monitoring was used throughout each
procedure to ensure a stable cardiac rhythm and pressure status. Antibiotics were administered
postoperatively by a veterinary technician. Also, pain medications were administered
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intramuscularly following surgery as needed or until the normal activity level of the animal was
resumed.
Autologous Stem Cell Isolation, Cultivation, and Labeling
Skeletal muscle samples were obtained from the rectus abdominius (skeletal) muscle at the
chest wall of the experimental animals during the first surgical procedure. The muscle was rinsed
with 70% ethanol followed by three rinses in Hank’s balanced salt solution lacking calcium and
magnesium but containing 1% antimycotic antibiotic solution (5ml of antibiotic added to 500ml
M-199). The tissue was minced and then incubated with 20 mL of enzyme solution (1%
collagenase and 0.2% hyaluronidase). After 10 minutes of incubation at 37ûC, the satellite cells
were harvested by pouring the solution through layers of sterile gauze into a sterile 50 mL
centrifuge tube and pelleted by centrifugation. The remaining tissue was incubated for 5 more
minutes in enzyme solution to complete the release of satellite cells from the muscle. The isolated
satellite cells were washed three times with medium-199 containing serum (10% fetal bovine
serum; 50ml added to 500ml of M-199) and 1% antibiotic antimycotic solution by centrifugation
and then resuspended. The cell number was counted using a hemocytometer. After proper
dilution, 1 X 106 cells were cultured with 8 mL of proliferation medium in a 25cm2 flask. The
isolated cells have a doubling time of approximately 22 hours. They can easily go though 20 cell
cycles and still retain their proliferation and differentiation properties. Cells were generally
labeled at 5-6 days after isolation when the cells were steadily growing and had adhered to the
flask. The cells were labeled via a viral tranfection method using humanized green fluorescent
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protein from Renilla reniformis. This humanized green fluorescent protein was added (0.8mL per
25cm2 flask) to the cells after removing the culture media. After a 3-hour incubation,
enough media to cover the bottom of the culture flask was supplied to the cells. Twenty-four
hours later the media was again replaced with fresh culture media. The fluorescence could be
observed in the cells as early as 48 hours post transfection using a fluorescent microscope with a
FITC filter.
Myocardial Infarction
During the first surgical procedure following skeletal muscle biopsy of the chest wall and
baseline recording measurements, the left anterior descending coronary artery was isolated and
the ameroid constrictor was placed around the vessel.
Cell Preparation for Implantation
After discarding the culture media, the satellite cells were rinsed with Hank’s Balanced
Salt Solution containing 1% antibiotic to removed any remaining serum that would prevent the
cells from detaching. Next, the cells were incubated in a 5:1 dilution of plain Hank’s Salt Solution
containing Trypsin and ETDA. The detachment of the cells from the flask was observed via a light
microscope and the cells were pelleted using centrifugation for five minutes and then were
resuspended in 4mL of plain M-199 culture media. The cell number was assessed using a
hemocytomer. Cells were kept sterile and when needed were poured into a 5mL syringe and then
injected into the injured myocardium. A representative aliquot of the cells were saved and allowed
to continue their proliferation in a 25cm2 flask to observe the growth of mononucleated satellite
cells into multinucleated myotubes. The reserved samples were fixed with buffered formaline and
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kept in phosphate buffered saline until pictures could be captured using the fluorescent
microscope with a FITC filter to observe the fluorescently labeled myotubes.
Laser Transmyocardial Revascularization (TMR)
At 3 weeks after the initial operation while under sterile surgical preparation and following
hemodynamic evaluation, the heart was exposed through a sternatomy. Laser TMR was
performed with an 800-W CO2 laser (The Heart Laser, PLC Medcial Systems, Milford, MA)
using a single 20-J pulse timed to the R wave of the EKG; 20 channels were created at 1 cm
intervals for the ischemic myocardium. After laser TMR and the establishment of hemostasis,
0.1mL of GFP labeled autologous satellite cells were injected at the center of each channel using a
syringe with a 25G hypodermic needle. The laser TMR control animals were subjected to the
same treatment but were injected with serum free culture medium. The carbon dioxide laser is
timed from the R-wave of the EKG to allow a successful channel to be made with the laser
instrument when the ventricle is blood-filled. The two groups of miniswine not receiving satellite
cell injections either received laser treatment followed by injections of plain culture medium into
the channels or no laser treatment and no injection. There also was a group of swine that received
satellite cell injections into the ischemic myocardium without experiencing the heart laser
treatment. After closing the sternum and incision, the animals recovered in cages and received the
same post-operative care and medication as at the time of the muscle biopsy and ameroid
constrictor placement.
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Hemodynamic Evaluation
The aortic and venous pressures were determined using Millar pressure transducers
(Millar Instruments, Inc., Houston, TX). The EKGs were recorded during each surgical
procedure using a Hewlitt Packard electrocardiogram 12-lead machine. The blood flow,
contractility, systolic wall thickening, pressures, and EKGs were integrated using the
computerized VF-1 hemodynamic system (Data Science Inc., St Paul, MN) and the Digital
Sonomicrometer (Sonometrics Co., London, Canada). Ultrasonic crystals were placed at the long
axis of the heart (crystals1-2), the short axis of the heart (crystals 3-4), across the depth of the left
ventricular free wall (crystals 3-5), and at the border of the ischemic area (crystals 6-7) (See
Figure 4). The cardiac output, pressure length loops, pressure volume loops, ejection fraction,
and stroke work were used to determine the global and local contractile functions.

Figure 4. Depicts sternatomy procedure of swine with crystals, constrictor, and pressure
transducers labeled.1. aorta 2. apex 3. anterior 4. posterior (under the heart) 5. myocardial
wall thickness 6. right infarct area 7. left infarct area ; LVP= left ventricular pressure transducer,
AP= arterial pressure transducer, C= ameroid constrictor
26

Global Contractility
A way to assess the pumping function of a particular heart is to evaluate the work loops
for that heart. The work loop is derived for each heart beat in real time and is a graphic
relationship between the changes in left ventricular pressure compared to the left ventricular
volume during a single heart beat (See Figure 5). The P-V loops were generated by
simultaneously recording ventricular pressure and volume in the working heart. Ventricular
pressure was obtained using an intra-ventricular pressure catheter. Left ventricular volume was
approximated by employing the equation for an ellipsoid, which is considered a well-established
method. By using a pair of crystals, one pair measuring the long axis (from the base to the apex)
and the other pair measuring the short axis (on the equatorial posterior and anterior LV free wall),
along with application of the ellipsoidal equation, the left ventricular volume was calculated per
animal per cardiac cycle.

Figure 5. Pressure-Volume Loop illustration which allows LV function assessment.
The left ventricular volume (LV V) comprises the x-axis and the left ventricular pressure
(LVP) comprises the y-axis. a. represents ventricular filling b. represents isovolumetric
contraction c. represents ventricular ejection d. represents isovolumetric relaxation SV=
stroke volume, ESPVR= end-systolic pressure volume relationship, EDPVR= enddiastolic pressure volume relationship, ESV= end-systolic volume, EDV= end-diastolic
volume (Richard E. Klabunde, www.cvphysiology.com, 2005)
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Generating pressure-volume loops allows the assessment of myocardial compliance or
commonly referred to as Emax. The Emax is the slope of the regression line that fits the endsystolic points on a pressure-volume loop after temporary occlusion of vena cava. Cardiosoft
determines these points by identifying the location in the cardiac cycle where the ration of
instantaneous pressure to instantaneous volume, minus the volume axis intercept, is greatest.
These points are located for all beats selected and used to calculate E-max.
Cardiac Output Cardiac output is basically a flow rate that is directly related to the heart
rate and stroke volume. Cardiac output is calculated on a beat-to-beat basis and the period is
defined from end diastole to end systole. Cardiac output is a function of the end-diastolic volume.
Cardiac output is expressed as the following equation:
CO = SV x HR
Ejection Fraction Ejection Fraction is the fraction of the end-diastolic volume ejected in
each stroke. Ejection Fraction is expressed as the following equation:
EF = SV / EDV
Regional Contractility
As the heart contracts and relaxes, the cardiac muscle undergoes various changes in wall
thickness and segmental shortening. The magnitude of these changes can be affected by a variety
of physiological and pathological processes. Therefore, quantification of these changes provided
valuable information concerning functionality and contractility. Segment shortening percentages

28

express the changes in segment length between the minimum distance and end diastole. Segment
shortening is expressed as the following equation:
SS%= [SL(ED)- SL(ES)] / SL (ED)
Regional Perfusion
The colored microspheres prepared by E-Z TRAC were crosslinked polystyrenedivinylbenzene microspheres. The method of animal preparation and microsphere injection with
the E-Z TRAC colored microspheres were the same as that followed with radioactive
microspheres in blood flow studies. To measure regional myocardial blood flow, the microspheres
were injected into the left ventricle of the experimental animal during each surgical procedure just
before chest closure. A line was placed into the left or right internal mammary artery, then a 2ml
solution was injected into the heart (1.4 ml sucrose solution and 0.6 ml microspheres), followed
by a reference blood sample collection at a rate of 15 ml/min for one minute with a syringe pump.
The reference blood sample was placed into a 50ml centrifuge tube with 0.1ml of heparin, labeled
with the pig identification number and date, and then blood reagent solution from E-Z TRAC was
added (see Figure 6). Once injected, the E-Z TRAC colored microspheres then mixed with the
arterial blood, distributed to the tissue, and ultimately lodged in the microvasculature. The number
of microspheres in the myocardial tissue of interest and in reference blood sample were
determined by following an extraction procedure using reagents and instructions supplied by E-Z
TRAC. After completing the process to retrieve the microspheres from the reference blood
sample or from the myocardial tissue, the spheres were counted using a hemocytometer.
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Figure 6. Microsphere Retrieval Process (Stason Pharmaceuticals [Internet]. Irvine, CA:
Interactive Medical Technologies; 2004 Sept. 10; Adapted from: http://www.stason.com/).
Statistical Analysis
A one-way ANOVA statistical test from Excel was used to compare the means among the
groups. Also, a non-parametric analysis, Kruskal-Wallis, with minitab software was used. A t-test
was used to assess the differences of the calculated values for each group of hearts at each time
point as compared to the group receiving only a coronary occlusion termed as Ischemia Group.
P<0.05 was considered significant in all statistical tests. This method of statistical
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analysis was used to assess statistical significance for all cardiac function values evaluated in this
project.
Heart Harvest
The animals were deeply anesthetized with halothane. The chest cavity was opened
exposing the heart. The heart was removed from the chest cavity, rinsed with 0.9% saline solution
and placed in a labeled, sealed bag to be frozen in order to section. Additionally, the animals were
heparanized prior to organ harvest, which inhibited blood clotting and enabled better tissue
cleanup.
Heart Sectioning
The heart was sectioned into 0.2 cm slices using a toastmaster platinum electric food
slicer. The tissue was then placed in iced buffered formaline. The heart tissue sections were then
processed, paraffin embedded, and sectioned by James H. Quillen’s pathology department’s
histology technician.
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CHAPTER 3
RESULTS
Isolation of Satellite Cells from the Skeletal Muscle of Miniswine
Light microscopy allowed morphological evaluation of the satellite cells. Figure 7
illustrates that in this experiment, satellite cell isolation, proliferation, and labeling were
successfully completed. Panel d of Figure 7 shows the formation of the satellite cells into
multinucleated myotubes and the presence of the fluorescence in the myotubes as well.

a

b

c

d

Figure 7. Light Microscopy Pictures of Swine satellite Cells a) early culture of passage 1 cells in
20% fetal bovine serum (FBS) b) early culture of cells with green fluorescent protein (GFP) label
c) formation of multinucleated myotubes from mononucleated cells d) multinucleated myotubes
with GFP label.
Cell Counts
No correlation could be made between number of injected cells and functional
improvement. However, this element of cellular cardiomyoplasty remains elusive despite the avid
interest in the question that remains: Is there a minimal or maximal cell implantation number
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necessary to have beneficial effects? In addition, the range of cells implanted in this experiment is
too close (1.3 X 106 to 6.5 X 106 cells) to have a meaningful evaluation for cell number and
functional recovery.
Pathological Evaluations
Sectioning the pig hearts allowed us to visualize the scar portion versus the area of viable
myocardium. Figure 8 illustrates the method used in sectioning the hearts. Pictures were taken of
these sections using a digital camera which allowed transference of this information into an
imaging program (See Figure 9). The imaging software made the scar area percentage calculation
possible through freehand visualization and interpretation. The chart (See Figure 10) shows the
percentages of scar area per group. A significant decrease in the scar area was found for the
ischemia + laser + cell group.
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Figure 8. Illustration of how the swine hearts were sectioned: C designated control region and (i)
designated the ischemic regionof the myocardium assigning two (1 & 3) of the tissue sections for
digestion for microsphere counts and two to be frozen (2 & 4) to be used for pathological
evaluation

1
4

2
3

Figure 9. Representative Heart Sections from each Animal Group A) Ischemia B) Ischemia +
Laser C) Ischemia + Laser + Cells D) Ischemia + Cells. Morphological evaluation of these heart
sections allows for the observation and comparison of the left ventricle (LV) scar area.
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Figure 10. Graphical Representation of Scar Area Differences
Heart sections from different groups and percent scar area differences; black bars indicate SEM
values; * represents a significant reduction in scar area in the TMR +cell and cell groups from the
ischemia group. Significance was assessed using a 1-way ANOVA (p<0.05).
Electrocardiograms
During the cardiac cycle, the electrical event precedes the mechanical. The
electrocardiogram (ECG or EKG) is the standard clinical tool used to evaluate the electrical
activity of the heart non-invasively. It is a graphic record of the sum of the cardiac action
potentials from different regions of the heart that can be picked up by recording electrodes from
the surface of the body as potential differences or voltage differences. These differences are
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recordable because of the timing and sequence of depolarization and repolarization of the heart.
Assessment of the height of various waveforms and the duration of the waveforms and their
various components allows insight into the normalcy or pathology of the electrical nature of the
heart. The electrocardiogram shown below (Figure 11) illustrates that what was seen in the pig
recordings at baseline (a normal sinus rhythm) and what was observed following LAD occlusion
(ST segment elevation indicative of myocardial injury).

A

B

Figure 11 Electrocardiogram showing lead II in both panels: A) Normal Sinus Rhythm of minipig
heart B) ST elevation & fibrillation (6th beat) after ischemic injury
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Hemodynamic Evaluations
The contractility and functionality of these hearts were evaluated in each pig at two
distinct but consistent time points. The measurements of the heart that enable the evaluation of the
function each heart were recorded using ultrasonic crystals attached at seven points on the heart
(discussed in more detail in the Materials and Methods section). These measurements were
obtained at a baseline value, before any treatment was elicited, and again just before termination,
nine weeks after the initial “normal” recordings. In comparing the different components of
function, the baseline value for each animal was designated as 100%. For each animal cardiac
output, segment-shortening, ejection fraction, and E-max were evaluated during each of the
surgeries. Measurements of hemodynamic parameters using 1-way ANOVA, t-tests, and KruskalWallis comparisons revealed no statistically significant differences (P=ns).
Cardiac Output
Cardiac Output is directly related to the stroke volume and heart rate. We evaluated
cardiac output for each group and expressed the values by assigning the recorded baseline
measurement as 100% as compared to the value obtained during the termination procedure. As
expected, two of the treatment groups, ischemia + laser and ischemia + laser + cells, showed clear
increase, though not statistically significant, in cardiac output as compared to the control
ischemic group. However, an unexpected result was the low output percentage values of the
group receiving ischemia + cells. The graph (Figure 12) represents the cardiac output percentages
for each of the four categories of animals. There was no significant difference observed in cardiac
output among the experimental groups, though there was a general observable trend that would
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require further research in order to determine whether the differences would reveal significance
using larger population samples as well as evaluating the animals progression at longer time
points.

Cardiac Output
250

Percentages

200

150

Ischemia
Ischemia + Laser
Ischemia + Laser + Cells
Ischemia + Cells

100

50

0
Groups

Figure 12. Graphical Representation of Cardiac Output: SEM indicated by black bar lines;
Significance was assessed using 1-way ANOVA. No significant statistical difference was found
among the groups (p=ns).
Ejection Fraction
Ejection Fraction is another assessment of global contractility and it is the ratio of the
stroke volume to the end-diastolic volume. There is no significant difference among the groups
(Figure 13). These values differ only modestly and revealed no significant functional difference in
the ejection fraction percentages using the baseline values as 100% across the groups.
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Ejection Fraction
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Ischemia + Laser
Ischemia + Laser + Cells
Ischemia + Cells

100
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0
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Figure 13. Graphical Representation of Ejection Fraction: SEM indicated by black bar lines.
Significance was assessed using 1-way ANOVA where no statistical significance was found
(p=ns).
Segment Shortening
Percent myocardial shortening in the LAD region is demonstrated below in Figure 14. The
SS% of the remote myocardium did not reveal differences among the first three groups. However,
there was a significant reduction of the regional contractility in the ischemia + cells group as
compared to the ischemia + laser group (p<.05). This was attributed this to the inflammatory
response as a result of the Gortex membrane used as a synthetic pericardium in an effort to reduce
adhesion formation seen in greater than 50% of the pigs from this particular group. Also, there

39

was noticeable reduction in regional contractility of the other two groups as compared to the
ischemia + laser group.

Segment Shortening (6-7)
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Percentages
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100

50

0
Groups

Figure 14. Graphical Representation of Segment Shortenin: SEM indicated by black bar lines
denotes significant difference between the ischemia + cells group as
compared to ischemia + laser group (p<0.05). Significance was assessed using 1way ANOVA followed by a t-test comparison.
Pressure-Volume Loops
A single left ventricular cycle of contraction, ejection, relaxation, and refilling can be
visualized using a pressure-volume loop. The pressure volume loops were generated by
simultaneously measuring the left ventricle using a pressure catheter and by evaluating the volume
of the left ventricle using the ultrasonic crystals. Several factors can elicit a alteration in the
pressure-volume loop from its baseline (normal) form. The stroke volume is the volume of blood

40

ejected from the ventricle on each heart beat and can be estimated using the pressure-volume
loops by subtracting the end-systolic volume from the end-diastolic volume. There was no
significant difference in stroke volume values among the groups (See Figure 15). The following
chart (See Table 1) lists the stroke volume (SV) values calculated for each animal of each animal
group category. The highlighted selection from each group was chosen using the average value
obtained for each animal group. Each highlighted animal was then used to create the
representative loops (See Figures 16-19) from each categorical group to observe what was
occurring during the cycle of the heart through the use of pressure-volume loops.
Stroke Volume

140
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100
Ischemia
Ischemia + Laser
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Ischemia + Laser + Cells
Ischemia + Cells

60

40

20

0
Groups

Figure 15. Graphical Representation of Stroke Volume: SEM indicated by black bar lines
denotes significant difference between the ischemia + cells group as compared to ischemia +
laser group (p<0.05). Significance was assessed using 1-way ANOVA, followed by t-test
comparison.
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Table 1. Stroke Volume Values and Averages per Animal and per Animal Group
The stroke volume values for each animal of each group and mean values for each group at
baseline and at sacrifice time points are listed.

Stroke Volume
Baseline

Sacrifice

Mean=

27
31
24.8
18.5
25.325

30
20
29.9
30
27.475

Mean=

28
12
26
16.6
53
26.9

27
28
36.2
27
15
26.55

Mean=

27.9
16.3
32.3
12.1
19
37
13.3
22.557

39.5
19.4
15.3
16.3
28
19
38.8
25.525

Mean=

25.4
29.1
27.9
22.5
26.225

17
11.9
11
40.4
20.075

Control
2015
3018
3023
3028

Laser
3003
3005
3008
3021
4008
Laser +
Cells
2016
2017
2018
2019
3004
3009
3010

Cells
3019
3022
4018
4019
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Figure 16. Representative p-v loops from the ischemia only animal group at baseline and sacrifice
time points. From Baseline to sacrifice, these Pressure-Volume (PV) loops show a marked
increase in the left ventricular volume, a stroke volume of approximate equal proportions and no
real change in the overall left ventricular pressure. However, both the end-diastolic and endsystolic volume increased a substantial amount.

Figure 17. Representative p-v loops from the ischemia + laser animal group at baseline and
sacrifice time points. In the representative loops from the Ischemia + Laser group, there was no a
great change in the overall left ventricular pressure or in the left ventricular volume from baseline
to sacrifice. The end-systolic volume and end-diastolic volume did decrease slightly but the
stroke volume remained relatively the same.
43

Figure 18. Representative p-v loops from the ischemia + laser + cells animal group at baseline
and sacrifice time points. From baseline to sacrifice, the ischemia + laser + cells representative
loops illustrated a rather large shift in left ventricular volume but the left ventricular pressure
remained relatively the same. The end-systolic and end-diastolic volumes dropped an observable
amount with only a slightly noticeable decrease in stroke volume.

Figure 19. Representative p-v loops from the ischemia + cells animal group at baseline and
sacrifice time points. In the ischemia + cells representative loops, there were observable increases
in left ventricular volume and pressure. The end-systolic and end-diastolic values both increased
but the overall stroke volume and stroke work decreased relatively.
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An increase in stroke volume is the result of an increase in end-diastolic volume, which is
the result of increased venous return (effects of changes in preload). The increase in stroke
volume is reflected in increased width of the pressure-volume (p-v) loop. The p-v loops that
indicated a decrease in stroke volume reflected the change with a decrease in the width of the p-v
loops. The decrease in stroke volume results in a decrease in end-systolic volume. In general, all
the loops show a decrease, in some cases very slight, in pressure from the normal or baseline
pressure-volume loop which can be viewed as a loss in height of the loop and correlates with
decreased contractility from baseline for each of the categories.
As mentioned, the slope of the line through the points at the end of the systole represents
the end-systolic pressure-volume relation (ESPVR) and is often used as an index of contractility.
Therefore, the slope remains unchanged without any accompanying changes in contractility even
with changes in preload or afterload. The slope of the line of the ESPVR for each loop for each
subject were compared and averaged across the groups using the baseline value as normal, or
100% (See Table 2). Again, there were no statistically significant differences among the groups
that were evaluated using 1-way ANOVA statistical analysis tests, accepting significance as a pvalue less than 0.05.
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Table 2. Load Variables and Averages per Animal and per Animal Group: Emax, EDPVR
(End-diastolic Pressure-Volume Relationship), & PRSW (Preload Recruitable Stroke Work) for
each group and the mean value per group. A 1-way ANOVA comparison of the means among the
groups reveals no significance (p=ns).
Load Variables
(values @
sacrifice)

Emax

EDPVR

PRSW

Ischemia

2015
3018
3023
3028
Mean

0.859
0.940
0.899
0.970
0.917

0.192
0.876
0.840
0.831
0.6847

0.464
0.974
0.948
0.966
0.838

I + Laser

3003
3005
3008
3021
4008
Mean

0.996
0.987
0.994
0.985
0.988
0.989

0.610
0.814
0.763
0.909
0.776
0.815

0.984
0.977
0.976
0.983
0.981
0.979

I + L+ Cells

2016
2017
2019
3004
3009
3010
Mean

0.983
0.971
0.511
0.995
0.934
0.983
0.856

0.831
0.810
0.101
0.926
0.915
0.489
0.608

0.976
0.420
0.869
0.990
0.538
0.965
0.841

I + Cells

3019
3022
4018
4019
Mean

0.470
0.989
0.998
0.927
0.846

0.288
0.558
0.658
0.487
0.498

0.597
0.204
0.623
0.757
0.545
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Regional Perfusion
The microspheres were used to compare regional perfusion as a result of angiogenesis or
lack thereof in each of the randomly assigned groups (See Table 3). There were only very slight
differences in the flow per gram per milliliter between the groups.
Table 3. Microsphere Counts to Measure Regional Perfusion. Represents microsphere counts
from the ischemic region of the myocardium per animal group category: LAD= left anterior
descending coronary artery; N= number of animals per group for regional perfusion analysis

Regional Myocardial blood flow (ml/100g/min)
LAD region
N

9 weeks post ameroid constrictor placement
Ischemia
Laser
Laser +Cells
Cells
44
46
48
42
3
4
3
3
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CHAPTER 4
DISCUSSION
Miniswine satellite cells were harvested and labeled successfully. Pathological evaluations
revealed significant scar area reductions in the cell + laser TMR and the cell groups. This exciting
result was puzzling because the hemodynamic analysis, which evaluated cardiac function, resulted
in no supporting functional improvement, specifically in the laser TMR + cells group. However,
since this loop was only a representative and did not include the entire group, its seemed
overreaching o use it to make any concrete claims, especially when considering the results of the
other functional parameters. In the laser TMR + cells group, the left ventricular volume was
decreased while maintaining cardiac output. The ischemia representative loop showed an increase
in left ventricular volume with a decreased cardiac output which together are indicative of a
failing heart. For all of the animal groups a 50% reduction was observed in the ejection fraction
values, which is not atypical following myocardial ischemia, however, it would seem worthwhile
to evaluate the ejection fraction at greater time intervals.
Autologous stem cell therapy has been shown to induce regeneration of viable
myocardium (Chiu et al. 1995). The mechanism behind this phenomena has yet to be elucidated
(Jingbo et al. 2004). According to the American Heart Association, cardiovascular disease (CD)
remains the number one killer of men and women in the United States. It was hypothesized that a
combination therapy using transmyocardial laser revascularization in addition to cellular
cardiomyoplasty would elicit angiogenesis and myogenesis in a chronic ischemic heart. The aim
of our study was to evaluate the effectiveness of combining these two therapeutic techniques
(Horvath et al. 2001).
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Laser TMR is FDA approved and has been used to treat patients suffering from chest pain
who do not otherwise qualify as participants in other traditional revascularization techniques.
However, previous studies in the CD literature have shown that autologous stem cell implantation
following ischemic injury results in improved ventricular function. (Jain et al.) However, whether
or not the implantation of satellite cells improves cardiac function has yet to be confirmed
(Wozniak et al. 2004). Based on these results, it is impossible to confirm or reject this implication
and therefore, no further insight has been gained into the mechanism behind the regeneration
phenomena. The lack of biochemical markers for satellite cells has made isolating a pure
population of these cells and the identification of these cells after implantation quite challenging.
For many years, the goal of advancing myocardial neovascularization has been studied in hopes of
providing an alternative therapy to those patients who cannot undergo conventional
revascularization (Yoon, Kao and Magovern 1995). Still, many questions surrounding this topic
remain: If there is an improvement seen following satellite cell implantation, what is the
mechanism? Once these cells are implanted into the injured myocardium, where do they go or
what do they become? Is there a best way to administer the implantation of the cells and is there a
necessary number of cells needed for implantation?
Over approximately the last 40 years, numerous experimental studies have been performed
to investigate the revascularization potential of transmyocardial revascularization and the possible
working mechanism underlying the observed clinical improvement in angina pectoris after this
treatment (Menno et al 2002). An acceptable explanation for this clinically observed relief has
not been found. Over the years, a number of hypotheses have been used to explain the
effectiveness seen with transmyocardial revascularization therapy. The “patent channel”
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philosophy has been somewhat recently dismissed as a possibility and has left “angiogenesis” and
“denervation” hypotheses competing for the “final answer.” However, since supportive evidence
has been presented which gives credit to both proposed mechanisms, it can be deduced that
perhaps both play a role in this phenomena. It is apparent that more clinical studies and further
research must be conducted in order to obtain a clearer understanding of the mechanism behind
laser TMR as well as to optimize the delivery of the therapy in general.
Implantation of autologous skeletal myoblasts (satellite cells) as an approach for
myocardial repair and functional improvement has been confirmed by other researchers (Bischoff
1994). The benefits of employing autologous satellite cells are further supported by more recent
publication and encouraging preliminary clinical evaluation by Kao and colleagues as well as
others (Jackson et al 2001). If favorable observations can be confirmed by rigorous clinical trials,
cellular cardiomyoplasty using autologous satellite cells may offer a new treatment. Although the
present study does not directly correlate with other findings, we believe that the introduction of an
additional unexpected inflammatory response from the Gortex membrane used as a synthetic
pericardium in an attempt to reduce adhesion formation may have greatly skewed the results for
the ischemia + cells group.
Regional myocardial blood flow analysis of this study indicated that relative blood flow
across the groups was not significantly different. Further research is needed to confirm this
observation because the population size may not have been large enough to fairly assess
significance between groups. There is little experimental information in the literature as to
whether transmyocardial laser revascularization improves long-term transmural perfusion and left
ventricular function in chronically ischemic myocardium. In a long-term study conducted by
Hughes and coworkers, regional contractility and perfusion were found to improve
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(Hughes 1999). Horvath and colleagues demonstrated an improved regional contractility at rest
in a chronic porcine model of myocardial ischemia, six weeks after transmyocardial laser
revascularization treatment (Horvath 1997). However, in contrast, Kohmoto and associates
measured regional myocardial blood flow using colored microspheres in an acute ischemic canine
model observing no significant differences in regional blood flow, which is consistent with these
results (Kohmoto et al 1998). Lutter and colleagues found that while CO2 –laser
revascularization may have an effect on microperfusion and regional contractility when under
stress, compared to their ischemia group of animals three months post chronic myocardial
ischemia, they found little to no effect on overall perfusion and global left ventricular function
(Lutter and Yoshitake 1998).
In his recent seminar on tissue engineering, Nerem (2005) stated that many of the
therapies of the 21st century will be of a combination nature. Our experiment to evaluate the
effectiveness of combining two therapies for cardiovascular disease corresponds to Nerem’s
prediction, but the results have left us asking the question: What can explain what we found
hemodynamically versus what we observed morphologically? Could it be that even though to the
naked eye the gross heart sections clearly showed less scar tissue and greater amounts of muscle
formation, these morphological improvements do not transfer into physiologic functional
improvements? Or could it be that the morphological differences are the first in a series of
improvements to be observed? In evaluating cardiac function using the transducing sonometric
crystals, we believe that the result of no statistically significant differences for each hemodynamic
aspect evaluated can be attributed to a number of factors/limitations.
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Limitations
Halothane was used as the inhalation agent in the anesthetic machine to maintain the
animals sedation throughout the surgical procedures. Even though halothane has been used
extensively for anesthesia in swine, it has been shown to induce generalized cardiovascular
depression and on occasion even elicit bradycardia (Tranquilli et al 1983). These actions are
manifested as lowered cardiac output and stroke volume values. The decrease in cardiac output is
associated with decreased left ventricular function (Duke et al. 1977). Even though we believe
the use of halothane as the anesthetic agent for this experiment could have had negative affects,
the fact that halothane was used for all the animals in all surgical procedures ensures equality for
comparisons among the groups.
Another limitation that could have influenced our findings was the small population used
for this experiment. Miniswine used for research purposed are costly animals to purchase,
maintain, and medicate. The sample size is a critical element of an experiment in order to ensure
enough study subjects to enable the detection of anticipated effects while determining the
minimum sample size required to do so.
Thirdly, the timescale for this experiment could have been too short. For the short
duration, the heart will compensate after ischemic injury; for example, a decrease in stroke volume
could be compensated by an increase in heart rate to maintain adequate cardiac output to sustain
the animal. However, over the long term, compensatory abilities will begin to fail, yielding
perhaps a more accurate assessment of the selected therapies.
Also, despite the fact that swine have been shown in investigative literature to be “the
animal of choice,” or at least one of them, in experiments such as this where redo open-chest
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procedures are required, these animals are challenging specimens (Sanders et al. 1977). The
fibrotic adhesions, which were unexpected, were extremely challenging to separate from the
pericardium to even be able to proceed with analysis. Additionally, without sedation the miniswine
do not easily tolerate typical monitoring methods, such as obtaining blood pressure, heart rate,
and temperature values.
Conclusion
To date, perhaps the most successful therapy used for cardiovascular disease is a heart
transplant. Unfortunately, the demand is increasing while the supply is not. Although our results
were not as we would have predicted, from aspects and observable trends in our data as well as
findings in other literature, we believe that the fusion of the proven benefits of medical device
technology, such as the CO2 heart laser in providing site-specific therapy with the pluripotent
attributes of emerging biologic therapeutics, and satellite cell implantation, creates tremendous
opportunity for revolutionary change in the way we view and treat disease. Further research,
perhaps using larger populations and longer-time intervals, will need to be conducted to discern
why such a static difference was observed between morphology and function.

53

REFERENCES

Abo-Auda W, Benza RL. Transmyocardial and percutaneous myocardial revascularization:
current concepts and future directions. J. Heart Lung Transplant.2003; 22:
837-42.
Allen et al. Adjunctive transmyocardial revascularization: five-year follow-up of a prospective,
randomized trial. Ann. Thorac. Surg. 2004; 78: 458-65.
Bischoff R. The satellite cell and muscle regeneration. Myology. Basic and clinical. 2nd
ed.1994. p 97-118.
Braunwald E. Heart diseases: a textbook of cardiovascular medicine. 5th ed. 1997. p1289365.
Bugaisky LB and Zak R. Differentiation of adult rat cardiac myocytes in cell culture. Circ.
Res. 1989; 64: 493-500.
Chachques JC, Duarte F, Cattadori B, Shafy A, Lila N, Chatellier G, Fabiani J N, Carpentier
A F. Angiogenic growth factors and/or cellular therapy for myocardial
regeneration: a comparative study. J. Thorac. Cardiovasc. Surg. 2004;
128: 245-53.
Chiu RC, Zibaitis A, and Kao RL. Cellular cardiomyoplasty: myocardial regeneration with
satellite cell implantation. Ann. Thorac. Surg. 1995; 60: 12-18.
Duke PC, Fownes D, and Wade JG. Halothane depresses baroreflex control of heart rate in
man. Anesthesiology. 1977; 46: 184.
Garrett WE Jr, and Best TM. Anatomy, physiology, and mechanics of skeletal muscle.
Orthopaedic basic science. Rosemont, IL: American Academy of
Orthopaedic Surgeons. 1994; p 89-125.
Hawke TJ and Garry DJ. Myogenic satellite cells: physiology to molecular biology. J. Appl.
Physiol. 2001; 91: 534-551.
Horvath KA, Aranki SF, Cohn LH, March RJ, Frazier OH, Kadipasaoglu KA, Boyce SW,
Lytle BW, Landolfo KP, Lowe JE, Hattler B, Griffith BP, Lansing AM.
Sustained angina relief 5 years after transmyocardial laser revascularization
with a CO(2) laser. Circulation. 2001; 104: (12 Suppl 1),181-4.
Horvath KA. Mechanimsms and results of transmyocardial laser revascularization.
Cardiology. 2004; 101: 37-47.
54

Huard J, Li Y, Fu FH. Muscle Injuries and Repair: Current Trends in Research. J. Bone &
Joint Surgery. 2002; 84A: 822-831.
Hurme T, Kallmo H. Activation of myogenic precursor cells after muscle injury. Med Sci
Sports Exerc. 1992; 24: 197-205.
Jackson KA et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult
stem cells. J. Clin. Invest. 2001; 107:1395-1402.
Jain, M, Dersimonian, H, Brenner, DA, et al. Cell therapy attenuates deleterious ventricular
remodeling and improves cardiac performance after myocardial infarction.
Circulation. 2001; 103: 1920-7.
Jingbo L et al. Autologous stem cell transplantation for myocardial repair. Am. J.Phys. Heart
Circ. Phys. 2004; 287:, H501-H511.
Kiortsis V, Koussoulakos S, Wallace H. eds. Recent trends in regeneration research. New
York: Plenum Press, 1989.
Kohmoto T, Derosa CM, Yamamoto N, et al. Evidence of vascular growth associated with
laser treatment of normal canine myocardium. Ann. Thorac. Surg. 1998;
63: 1275-83.
Lash J, Holtzer H, Swift H. Regeneration of mature skeletal muscle. Anat. Rec. 1957; 128:
679-698.
Li F, Wang X, Capasso JM, Gerdes AM. Rapid transition of cardiac myocytes from
hyperplasia to hypertrophy during postnatal development. J Mol Cell
Cardiol. 1996; 28: 1737-46.
Lutter G, Yoshitake M, Takahashi N, Nitzsche E, Martin J, Sarai K, Lutz C, Beyersdorf F.
Transmyocardial laser-revascularization: experimental studies on prolonged
acute regional ischemia. Eur J Cardiothorac Surg. 1998; 13(6): 694-701.
Marelli D, Desrosiers C, el-Alfy M, Kao RL, Chiu RC. Cell transplantation for myocardial
repair: an experimental approach. Cell Transplant 1992; 1: 383-90.
Mauro A. Satellite cell of skeletal muscle fibers. J. Biophys. Biochem. Cytol. 1961; 9: 493-5.
Menasche P, Hagege AA, Vilquin J-T, et al. Autologous skeletal myoblast transplantation for
severe postinfarction left ventricular dysfunction. J. Am. Coll. Cardiol.
2003; 41: 1078-83.
55

Menno H, Beek JF, Van der Sloot JAP, Tukkie R, Van der Meulen J. Thirty-Five years of
experimental research in transmyocardial revascularization: what have we
learned? Ann. Thorac. Surg. 2002; 74: 956-70.
Rumyantsev PP. Interrelations of the proliferation and differentiation processes during cardiac
myogenesis and regeneration. Int. Rev. Cytol. 1977; 51: 186-273.
Rumyantsev PP. Reproduction of cardiac myocytes developing in vivo and its relationship to
processes of differentiation. In: Rumyantsev PP, ed. Growth and
hyperplasia of cardiac muscle cells. New York: Academic Press, 1991: 70159.
Samuels L, Emery R, Lattouf O, Grosso M, AlZeerah M, Schuch D, Wehberg K, Muehrcke
D, Dowling R. Transmyocardial laser therapy: a strategic approach. Heart
Surg. Forum.2004; 7(3): E218-29.
Sanders M, White F, Bloor C. Cardiovascular responses of dogs and pigs exposed to similar
physiological stress. Comp. Biochem. Physiol. 1977; 58A: 365.
Schultz E, Gibson MC, Champion T. Satellite cells are mitotically quiescent in mature mouse
muscle: an EM and radioautographic study. J. Exp. Zool. 1978; 206: 451456.
Schultz E, McCormick KM. Skeletal muscle satellite cells. Rev. Physiol. Biochem.
Pharmacol. 1994; 123: 213-257.
Snow MH. An autoradiographic study of satellite cell differentiation into regenerating
myotubes following transplantation of muscles in young rats. Cell Tissue
Res. 1978; 186: 535-40.
Sophie B, Charge P, Rudnicki MA. Cellular and Molecular Regulation of Muscle
Regeneration. Physiol. Rev. 2004; 84: 209-238.
Taylor DA, Atkins BZ, Hungspreugs P, et al. Regenerating functional myocardium: improved
performance after skeletal myoblast transplantation. Nat. Med. 1998; 4:
929-33.
Tranquilli WJ, Thurman JC, Benson GJ, Steffey EP.Halothane potency in pigs. Am. J. Vet.
Res. 1983; 44:(6), 1106.
Whittaker P, Kloner RA. Transmural channels as a source of blood flow to ischemic
myocardium? Circulation 1997; 95: 1357-9.

56

Wozniak AC, Kong J, Bock E, Pilipowicz O, Anderson JE. Signaling satellite-cell activation
in skeletal muscle: Markers, models, stretch, and potential alternate
pathways. Muscle Nerve. 2004; 31(3):283-300.
Yoon PD, Kao RL, Magovern GJ Myocardial regeneration. Transplanting satellite cells into
damaged myocardium. Tex. Heart Inst. J. 1995; 22(2):119-25.
Young HE, Black AC Jr. Adult Stem Cells. Anatomical Record. 2004; 276A: 75-102.

57

VITA
ESHA IBRAHIM

Personal Data: Date of Birth: June 12, 1979
Place of Birth: Johnson City, Tennessee
Marital Status: Single
Education:

Professional
Experience:

Elizabethton High School, Elizabethton, Tennessee
East Tennessee State University, Johnson City, Tennessee;
Biology, B.S., 2000
East Tennessee State University, Johnson City, Tennessee;
Physiology, M.S., 2005

Graduate Assistant, East Tennessee State University, College of
Medicine, 2003 – 2005
Poster Presentation at 18th annual Research Forum at ETSU, 2002
Poster Presentation at 19th annual Research Forum at ETSU, 2003
Poster Presentation at TAS conference in Johnson City, Tennessee
Poster Presentation at FASEB conference in Washington, D. C.
Poster Presentation at FASEB conference in New Orleans, Louisiana

Publications: Kao RL, Chin TK, Ibrahim E, Davis J and Browder W. Induced neomyocardial
formation after heart attack. Circulation, 104: II-599, 2001.
Ibrahim E, Chin T, Davis J and Kao RL. Pharmacologic myocardial regeneration
using 5-Aza-2'-deoxycytidine. FASEB J. 16: A491, 2002
Kao, R.L., Ibrahim E., Davis, J., Zhu Q., Ganote, C.E., Pennington, D.G.
Autologous stem cells and Transmyocardial laser Revascularization for myocardial
infarction. Circulation, October, 2003.
Carter JE, Hossler FE, Li C, Davis J, Ibrahim ED and Kao RL. Bone marrow
stromal cells and angiogenic factors for myogenesis and angiogenesis after
myocardial infarction. Cardiovasc. Radiat. Med. 3: 244, 2003
58

Ibrahim ED, Davis J, Chin TK, Kao RL. Drug induced myocardial regeneration
after myocardial infarction. Cardiovasc. Radiat. Med. 3: 244, 2003.

59

